Atossa Therapeutics Announces Successful In Vitro Testing of Nasal Spray Formulation: AT-301 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture
15 Jul, 2020
Results Support Development of Proprietary AT-301 Nasal Spray for COVID-19 Patients
Get A Free Gift
Your Mammogram: The Questions to Ask Before, During, and After Your Exam
Coronavirus Survival Manual
A Physician's Guide to Keep You and Your Family Healthy During the Pandemic and Beyond
